DOUG DANISON

SVP, Head of Europe, Bluebird Bio

Doug Danison joined bluebird bio in July 2015 charged with establishing the global pricing, market access, and health economics team known as Access Value & Evidence Strategy (AVES).  Doug led the creation of bluebird bio’s market access strategy and the hiring of the Global, European, and US AVES teams.  Doug was promoted to Head of Europe in January 2021 and now oversees all of bluebird bio’s operations in Europe, carrying on his strong market access background with the addition of a broader remit.

Doug has more than 20 years of commercial experience, including roles with Eli Lilly & Company, Amgen, Millennium/Takeda Oncology and now bluebird bio, he has led or overseen the preparation of market access strategies for products in early development, pivotal study planning, launch, and post launch lifecycle management.  He has addressed market access challenges from a variety of vantage points including Global, European Regional, and US roles. He has built teams, processes, and a knowledgebase that enables the execution of commercial strategies with a focus on oncology and cell and gene therapy.